Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Eloxx Pharmaceuticals, Inc.

Ticker
ELOX
Sector
Industry
Report date
November 17, 2026
Valye AI Score

74

High visibility
Recent developments
Recent developments summary
Recent developments:
Overview

Eloxx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company specializing in treatments for rare genetic diseases. Its lead product candidate, exaluren, is undergoing clinical evaluation in Phase 2 trials targeting genetic kidney diseases such as Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD). The company engages with the FDA on regulatory pathways including Breakthrough Therapy Designation and accelerated approval, although these are contingent on clinical trial outcomes and FDA discretion. Eloxx has no commercial products or revenue to date and finances its operations through equity offerings and capital raises. The company reported a net loss in recent quarters and maintains a strong liquidity position with over $56 million in cash and equivalents as of Q3 2026.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases. The company is advancing its lead candidate, exaluren, through multiple clinical trials including Phase 2 studies for genetic kidney diseases and Alport syndrome. Recent FDA clearance for the exaluren Phase 2 trial and finalized Phase 2 ADPKD trial design reflect ongoing regulatory engagement. Eloxx reported a net loss of $5.543 million for Q3 2026 and held $56.3 million in cash and equivalents as of September 30, 2026, with strong liquidity ratios. The company continues to incur higher costs related to clinical development and is pursuing regulatory designations that may impact development timelines. Recent corporate developments include board appointments and a registered direct offering completed in 2026.

Scenarios for ELOX

Bull case model:

Eloxx Pharmaceuticals has advanced its lead candidate exaluren into multiple Phase 2 clinical trials, including for genetic kidney diseases such as Alport syndrome and ADPKD, with FDA clearance obtained for a Phase 2 trial. The company has demonstrated the ability to raise capital, including a $66 million offering in 2026, supporting ongoing development. Positive clinical data and regulatory designations could enhance the company's development pathway and market positioning. Recent board appointments and clinical updates indicate active management and strategic focus.

Bear case model:

Eloxx Pharmaceuticals remains a clinical-stage company with no approved products or revenue, incurring net losses and higher costs related to clinical development. Regulatory pathways such as Breakthrough Therapy Designation and accelerated approval are uncertain and subject to FDA discretion and clinical trial outcomes. Failure to demonstrate clinical efficacy or safety could delay or prevent approval. The company faces risks typical of biotech firms including clinical, regulatory, and financing challenges, which could impact its operational and financial stability.

Moat:

Eloxx Pharmaceuticals' moat is primarily based on its focus on rare genetic diseases with limited existing treatment options, and its development of exaluren, a novel therapeutic candidate targeting genetic kidney disorders. The company's engagement with the FDA and ongoing clinical trials contribute to potential regulatory barriers for competitors. However, as a clinical-stage biopharmaceutical company without approved products or revenue, its competitive position depends heavily on successful clinical development and regulatory approvals, which remain uncertain.

Risks overview
Risks summary
The primary risks for Eloxx Pharmaceuticals relate to clinical trial outcomes and regulatory approval uncertainties, which directly affect its ability to commercialize its lead candidate and achieve financial sustainability.
Risks details:

• Clinical Development Risk: Eloxx's lead candidate exaluren is in early-stage clinical trials, and there is risk that the trials may not demonstrate sufficient efficacy or safety to support regulatory approval.
• Regulatory Risk: The company’s pursuit of Breakthrough Therapy Designation and accelerated approval is subject to FDA discretion and preliminary clinical evidence, which may not be granted or may not expedite approval.
• Financial Risk: Eloxx has reported net losses and relies on capital raises to fund operations. Continued losses and the need for additional financing may dilute shareholders or constrain operations.
• Market and Competitive Risk: As a clinical-stage biotech, Eloxx faces competition from other companies developing treatments for rare genetic diseases, which could impact its market potential.

FINAL FORECAST FOR ELOX

Final take one line
Final take 12 to 24 month view
Valye AI Visibility Research Score

High visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

74
LLM visibility overview
LLM Visibility known facts
  • Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases.
  • The company is conducting clinical trials for its lead candidate, exaluren, including a Phase 2 trial for genetic kidney disease and a Phase 2b trial for Alport syndrome, with data expected mid-2027.
  • Eloxx received FDA clearance for the exaluren Phase 2 trial in genetic kidney disease as of October 2026.
  • The company finalized Phase 2 ADPKD trial design following FDA feedback and appointed a new Chief Medical Officer in October 2026.
  • Eloxx appointed Geno J. Germano to its board in October 2026.
  • Cantor Fitzgerald initiated coverage of Eloxx Pharmaceuticals at overweight in October 2026.
  • The company reported a net loss of $5.543 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.49 per share.
  • As of September 30, 2026, Eloxx had $56.3 million in cash and cash equivalents, current assets of $58.3 million, and current liabilities of $17.2 million, resulting in a current ratio of 3.39 and a cash ratio of 3.27.
  • Eloxx has no reported revenue as of the latest filings, consistent with its clinical-stage status.
  • The company issued options to purchase 120,875 shares of common stock to employees and directors in late 2026.
  • Recent quarterly losses have widened due to higher costs associated with clinical development.
  • The company is pursuing regulatory pathways including Breakthrough Therapy Designation and accelerated approval for exaluren, though these are subject to FDA discretion and clinical data outcomes.
  • Eloxx completed a $66 million registered direct offering and uplisted to Nasdaq in mid-2026.
Sources
Sources - Context summary

Generated 2026-11-17

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-16 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-17 | www.nasdaq.com | Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update | https://www.nasdaq.com/articles/eloxx-pharmaceuticals-reports-third-quarter-2026-financial-results-and-provides-business
  • N2 | 2026-11-16 | www.nasdaq.com | Eloxx Q3 Loss Widens On Higher Costs; Alport Phase 2b Trial Data Due Mid-2027 | https://www.nasdaq.com/articles/eloxx-q3-loss-widens-higher-costs-alport-phase-2b-trial-data-due-mid-2027
  • N3 | 2026-10-29 | www.nasdaq.com | Eloxx Gains FDA Clearance For Exaluren Phase 2 Trial In Genetic Kidney Disease | https://www.nasdaq.com/articles/eloxx-gains-fda-clearance-exaluren-phase-2-trial-genetic-kidney-disease
  • N4 | 2026-10-22 | www.nasdaq.com | Eloxx Pharmaceuticals Appoints Geno J. Germano to Board on October 19, 2026 and Announces Clinical Update | https://www.nasdaq.com/articles/eloxx-pharmaceuticals-appoints-geno-j-germano-board-october-19-2026-and-announces-clinical
  • N5 | 2026-10-15 | www.nasdaq.com | Cantor Fitzgerald Initiates Coverage of Eloxx Pharmaceuticals at Overweight | https://www.nasdaq.com/articles/cantor-fitzgerald-initiates-coverage-eloxx-pharmaceuticals-overweight
  • N6 | 2026-08-21 | www.nasdaq.com | Top Biotech Gainers: ELOX Clinical Progress, VOGX IPO Success, ARCT Pipeline Updates Drive Gains | https://www.nasdaq.com/articles/top-biotech-gainers-elox-clinical-progress-vogx-ipo-success-arct-pipeline-updates-drive
  • N7 | 2026-08-21 | www.nasdaq.com | Eloxx Q2 Loss Widens; Exaluren Phase 2b Trial Set To Begin In Q3 2026 | https://www.nasdaq.com/articles/eloxx-q2-loss-widens-exaluren-phase-2b-trial-set-begin-q3-2026
  • N8 | 2026-08-12 | www.nasdaq.com | Eloxx Pharmaceuticals, Inc. Loss At -$4.50 Mln In Q2 | https://www.nasdaq.com/articles/eloxx-pharmaceuticals-inc-loss-450-mln-q2
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine